In T-ALL, there have been mixed reports regarding its prognostic roles; some demonstrated inferior outcomes in patients with mutated PHF6 [21] whereas others showed no significant differences in outcomes from those with wild-type PHF6 [22, 23]. This evidence concerns the gene PHF6 and acute lymphoblastic leukemia.